
Verastem (VSTM) Stock Forecast & Price Target
Verastem (VSTM) Analyst Ratings
Bulls say
Verastem is a biopharmaceutical company in late-stage development with a promising pipeline and multiple drugs in various stages of development, including daraxonrasib, VS-7375, and a KRASG12D inhibitor. The company has also reported success with current treatments, mFOLFIRINOX and NALIRIFOX, and potential for partnerships in the EU. With a strong focus on low-grade serous ovarian cancer and projected peak sales of $292M, Verastem shows great potential for growth in the cancer treatment market.
Bears say
Verastem is relying on significant collaborations for the commercialization of its pipeline products with projected peak sales of $1.4B. However, the company's heavy safety profile raises concerns about the tolerability of these products. In addition, while some combination therapies have shown promising response rates, the DCR remains stagnant, indicating limited effectiveness. Despite advancements in late-stage trials, the company's reliance on partnerships makes it vulnerable to delays or setbacks in commercialization, potentially hindering its potential for growth.
This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.
Verastem (VSTM) Analyst Forecast & Price Prediction
Start investing in Verastem (VSTM)
Order type
Buy in
Order amount
Est. shares
0 shares